|Day Low/High||10.50 / 10.80|
|52 Wk Low/High||9.59 / 29.67|
Sucampo Pharmaceuticals, Intellia Therapeutics and Cytokinetics were among the biotech stock movers in premarket trading on Wednesday.
Investors in Sucampo Pharmaceuticals Inc saw new options begin trading this week, for the September 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The most recent short interest data has been released for the 12/15/2016 settlement date, which shows a 882,451 share increase in total short interest for Sucampo Pharmaceuticals Inc , to 3,241,596, an increase of 37.41% since 11/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Investors in Sucampo Pharmaceuticals Inc saw new options become available this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SCMP options chain for the new February 2017 contracts and identified the following call contract of particular interest.
The number of new 12-month highs has climbed to 240.
There simply aren't many compelling trades on my screen.
Investors in Sucampo Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SCMP options chain for the new November 18th contracts and identified the following call contract of particular interest.
Investors considering a purchase of Sucampo Pharmaceuticals Inc stock, but tentative about paying the going market price of $13.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $10 strike, which has a bid at the time of this writing of 75 cents.
Trade-Ideas LLC identified Sucampo Pharmaceuticals (SCMP) as a weak on high relative volume candidate
It's an irrational time for the stock market, Cramer says.